Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone734-887-3903
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees76
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions
What is Esperion Therapeutics' stock symbol?
Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."
How were Esperion Therapeutics' earnings last quarter?
Esperion Therapeutics Inc (NASDAQ:ESPR) issued its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($2.01) earnings per share for the quarter, missing analysts' consensus estimates of ($1.86) by $0.15. The biopharmaceutical company earned $0.98 million during the quarter, compared to analysts' expectations of $1.05 million. The firm's quarterly revenue was up 9720.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.71) EPS. View Esperion Therapeutics' Earnings History.
When is Esperion Therapeutics' next earnings date?
What price target have analysts set for ESPR?
11 brokerages have issued 1-year price objectives for Esperion Therapeutics' stock. Their forecasts range from $45.00 to $114.00. On average, they expect Esperion Therapeutics' share price to reach $71.60 in the next year. This suggests a possible upside of 83.7% from the stock's current price. View Analyst Price Targets for Esperion Therapeutics.
What is the consensus analysts' recommendation for Esperion Therapeutics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 4 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Esperion Therapeutics.
What are Wall Street analysts saying about Esperion Therapeutics stock?
Here are some recent quotes from research analysts about Esperion Therapeutics stock:
- 1. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and lowering our target price to $70 which reflects a more conservative pre-CVOT BPA/combo sales ramp and higher SG&A assumptions. Even with our more conservative forecasts, we believe ESPR is undervalued at these levels (EV of ~$700 million) as we think the stock continues to reflect investor skepticism on the commercial opportunity for BPA/ combo and the company’s cash runway. We view BPA/combo as a clinically de-risked asset with two upcoming and believe BPA’s CVOT design portends a high probability of success. Further, our recent KOL checks have been consistent with our past discussions (see deep dive) in validating what we believe is a meaningful commercial opportunity for BPA/combo in the statin intolerant population." (9/17/2019)
- 2. Northland Securities analysts commented, "We are now modeling $0.69 in non-GAAP EPS on $97.8 million in revenue for FY/19." (8/29/2019)
- 3. Chardan Capital analysts commented, "We find the relevant statistical analyses in the NEJM publications roughly consistent with those of our consulted biostatisticians and still see the following open issues as unresolved:." (3/14/2019)
- 4. According to Zacks Investment Research, "Esperion has no approved products in its portfolio. It focuses on developing new oral therapies for LDL-C lowering indications. The company’s pipeline products, bempedoic acid pill and bempedoic acid/Zetia combination pill achieved significant reduction in elevated bad cholesterol levels in hypercholesterolemia patients. The targeted area represents a significant opportunity. Esperion plans to file regulatory applications for both the candidates in the United States and Europe in the first half of 2019. However, Esperion neither has a marketed product nor a collaboration agreement to generate funds to support development and commercialization of its pipeline candidates. Esperion's share have outperformed the industry in past six months. Loss estimates have been stable ahead of Q4 earnings. Esperion has a mixed record of earnings surprise in the recent quarters." (2/8/2019)
Has Esperion Therapeutics been receiving favorable news coverage?
Headlines about ESPR stock have trended neutral recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Esperion Therapeutics earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Esperion Therapeutics.
Are investors shorting Esperion Therapeutics?
Esperion Therapeutics saw a drop in short interest in September. As of September 30th, there was short interest totalling 5,030,000 shares, a drop of 7.0% from the August 30th total of 5,410,000 shares. Based on an average daily volume of 421,100 shares, the short-interest ratio is presently 11.9 days. Approximately 19.9% of the company's stock are sold short. View Esperion Therapeutics' Current Options Chain.
Who are some of Esperion Therapeutics' key competitors?
Some companies that are related to Esperion Therapeutics include The Medicines (MDCO), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), GW Pharmaceuticals PLC- (GWPH), United Therapeutics (UTHR), FibroGen (FGEN), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), Mirati Therapeutics (MRTX), Allakos (ALLK), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Reata Pharmaceuticals (RETA) and Global Blood Therapeutics (GBT).
What other stocks do shareholders of Esperion Therapeutics own?
Who are Esperion Therapeutics' key executives?
Esperion Therapeutics' management team includes the folowing people:
- Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 58)
- Dr. Narendra D. Lalwani, Exec. VP of R&D (Age 66)
- Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 37)
- Mr. Alexander Duke Schwartz, Sr. Director of Investor Relations
- Ms. Marianne Andreach, Sr. VP
How do I buy shares of Esperion Therapeutics?
Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Esperion Therapeutics' stock price today?
One share of ESPR stock can currently be purchased for approximately $38.97.
How big of a company is Esperion Therapeutics?
Esperion Therapeutics has a market capitalization of $1.06 billion. The biopharmaceutical company earns $-201,810,000.00 in net income (profit) each year or ($7.54) on an earnings per share basis. Esperion Therapeutics employs 76 workers across the globe.View Additional Information About Esperion Therapeutics.
What is Esperion Therapeutics' official website?
How can I contact Esperion Therapeutics?
Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]
MarketBeat Community Rating for Esperion Therapeutics (NASDAQ ESPR)
MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe ESPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
